NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Gastroenterology and Mucosal Immunity > Paper urges use of genomics in care of monogenic IBD

Paper urges use of genomics in care of monogenic IBD

5 January 2021 · Listed under Gastroenterology and Mucosal Immunity

Gastroenterology experts have had a position paper published that calls for genomic technologies to be considered an integral part of patient care to investigate patients at risk for monogenic forms of inflammatory bowel disease (IBD).

The authors include a number of NIHR Oxford BRC-supported researchers.

The paper, published in the Journal of Paediatric Gastroenterology and Nutrition, pointed out the importance of identifying patients with monogenic IBD since management of their condition may differ from classical IBD.

The paper was endorsed by specialists from the Paediatric IBD Porto group of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and from several monogenic IBD research consortia.

“We recommend next-generation DNA sequencing technologies to diagnose monogenic causes of IBD in routine clinical practice embedded in a setting of multidisciplinary patient care,” the paper concludes.

It said that routine genetic screening is not recommended for all IBD patients: “Genetic testing should be considered depending on age of IBD onset and criteria such as family history, relevant comorbidities and extra-intestinal manifestations. Genetic testing is also recommended in advance of hematopoietic stem cell transplantation.”

The authors have also developed a diagnostic algorithm that includes a gene panel of 75 monogenic IBD genes.

← IBD treatments do not increase susceptibility to COVID-19, study finds
Oxford collaborates with Janssen to map the cellular landscape of immune mediated disorders →

News

  • NIHR Advance Fellowship awarded 19 April 2021
  • Human challenge trial launches to study immune response to COVID-19 19 April 2021
  • What Matters Most: A workshop methodology to hear patients’ priorities 16 April 2021
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page